# Systemic Sclerosis in a Seven-Year-Old Girl Responding to Mycophenolate Mofetil: A Case Report

## TL;DR

A seven-year-old girl with juvenile systemic sclerosis showed improvement with mycophenolate mofetil treatment.

## Contribution

This case report highlights the successful use of mycophenolate mofetil in treating juvenile systemic sclerosis.

## Key findings

- The patient showed improvement after treatment with mycophenolate mofetil.
- Early diagnosis and intervention are crucial for managing juvenile systemic sclerosis.
- Anti-Scl-70 antibodies were detected, supporting the diagnosis of JSSc.

## Abstract

Juvenile systemic sclerosis (JSSc) is a chronic, multisystem, connective tissue disease typically characterized by symmetrical fibrous thickening and hardening of the skin combined with fibrous changes in internal organs, such as the esophagus, intestinal tract, heart, lungs, and kidneys. We present the case of a seven-year-old female with a history of chest pain, irregular episodes of vomiting, and shortness of breath. Physical examination revealed hardening of the skin and darkish discoloration prominent on arms. Blood serology showed a positive anti-Scl-70 antibodies test, suggestive of JSSc. Treatment with prednisolone was initiated, followed by mycophenolate mofetil (MMF). This case highlights the importance of considering MMF in the treatment of patients with JSSc. Early diagnosis and intervention are essential in optimizing the quality of life for patients with JSSc.